Changing use of hormone therapy among minority women since the Women's Health Initiative
- 1 March 2007
- journal article
- Published by Wolters Kluwer Health in Menopause
- Vol. 14 (2) , 216-222
- https://doi.org/10.1097/01.gme.0000233169.65045.b1
Abstract
There has been a significant shift in the use of hormone therapy (HT) among nonminority women since the publication of results of the Women's Health Initiative (WHI). Little is known about how the WHI results affected minority populations. This survey measured patterns of HT use among inner city women after publication of the WHI results, identified factors involved in the decision to continue or discontinue HT, and characterized the symptom burden and the experience of women who attempted to discontinue HT. We conducted a cross-sectional survey of 101 English- and Spanish-speaking women in an inner city general internal medicine clinic from August 2003 to April 2004. All women had been taking HT at the time of the publication of the WHI results. The survey included questions on patient-reported experience with HT, symptoms of menopause, and use of alternative treatments. Overall, 101 of 142 (71%) eligible women agreed to participate. The mean age of participants was 60 years; 43% were African American and 46% were Hispanic. The mean duration of HT use was 9.6 years. Three quarters (74%) had heard about the WHI findings, and 87% had attempted to stop taking HT after their publication. The most common reason for attempting to stop HT was concern about an increased risk of cancer or a general increase in risk to health. Of those who stopped HT, the vast majority (85%) reported vasomotor symptoms, and 26% restarted HT, mostly to treat those symptoms. Nearly all minority women in this small sample attempted to stop HT use after the results of the WHI were published. Restarting HT for treatment of symptoms was common.Keywords
This publication has 20 references indexed in Scilit:
- The impact of the Women's Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in GermanyMenopause, 2005
- Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause SocietyMenopause, 2004
- The Impact of the Women's Health Initiative on Discontinuation of Postmenopausal Hormone Therapy: The Minnesota Heart Survey (2000–2002)Journal of Women's Health, 2004
- The Impact of the Women's Health Initiative on Hormone Replacement Therapy in a Medicaid ProgramJournal of Women's Health, 2004
- Use of menopausal hormones in the United States, 1992 through June, 2003Pharmacoepidemiology and Drug Safety, 2004
- Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial ResultsAnnals of Internal Medicine, 2004
- National Use of Postmenopausal Hormone TherapyJAMA, 2004
- Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of usersBMJ, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Ethnic differences in hormone replacement prescribing patternsJournal of General Internal Medicine, 1999